类型Ia抗心律不良药对心脏病发作后患者的低脂效应
1Cardiology Section, Department of Veterans Affairs Medical Center, Boston.
Circulation
|June 1, 1992
概括
类型Ia抗心律不良药在心脏病发作后的患者中显著降低胆固醇,甘油三和阿波蛋白B水平. 这种在冠状动脉心脏病患者中观察到的低脂效应,需要进一步研究其潜在机制.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 脂质代谢 脂质代谢是什么
背景情况:
- 胆固醇和阿波蛋白B (apo B) 的升高是早期冠心病的关键风险因素.
- 抗心律不整的药物通常用于冠状动脉疾病和心律不整的患者.
研究的目的:
- 为了研究抗心律失常药物对心脏病发作后患者血脂概况的影响.
- 为了确定IA型抗失常药是否会影响胆固醇,甘油三和阿波蛋白水平.
主要方法:
- 对1,567名心脏病发作后患者的回顾性分析,以前性收集的脂质和药物数据.
- 总胆固醇,甘油三,高密度胆固醇 (HDL C) 和阿波蛋白A-I (apo A-I),A-II (apo A-II) 和阿波B的分析.
- 使用t测试和多重回归分析,比较接受和不接受Ia型抗失常药物的患者之间的脂质水平.
主要成果:
- 服用Ia型抗失常药物的患者显示胆固醇 (8.6%),甘油三 (22.3%),apo A-I (6.2%),apo A-II (10.1%) 和apo B (12.7%) 的水平显著降低.
- 这些减少在统计学上是显著的 (apo B的p < 0.0001),并且在调整共变量后仍然存在.
- 高密度脂蛋白胆固醇 (HDL C) 水平在两组之间没有显著差异.
结论:
- 类型Ia抗失常药与显著降低胆固醇,甘油三,ApoA-II和ApoB水平有关.
- 这些药物的低脂效应尚未完全理解,但可能涉及肝细胞离子膜电流的改变.
- 需要进一步的研究来阐明这种观察到的降脂效应背后的机制.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...